Global Capecitabine Market Growth 2023-2029

Global Capecitabine Market Growth 2023-2029

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.

LPI (LP Information)' newest research report, the “Capecitabine Industry Forecast” looks at past sales and reviews total world Capecitabine sales in 2022, providing a comprehensive analysis by region and market sector of projected Capecitabine sales for 2023 through 2029. With Capecitabine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Capecitabine industry.

This Insight Report provides a comprehensive analysis of the global Capecitabine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Capecitabine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Capecitabine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Capecitabine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Capecitabine.

The global Capecitabine market size is projected to grow from US$ 1003.9 million in 2022 to US$ 975.1 million in 2029; it is expected to grow at a CAGR of 975.1 from 2023 to 2029.

Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.

This report presents a comprehensive overview, market shares, and growth opportunities of Capecitabine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
500 mg
150 mg

Segmentation by application
Breast Cancer
Colorectal Cancer
Stomach Cancer

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero

Key Questions Addressed in this Report

What is the 10-year outlook for the global Capecitabine market?

What factors are driving Capecitabine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Capecitabine market opportunities vary by end market size?

How does Capecitabine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.